Metin Kurtoglu, Chief Technology Officer at Cartesian Therapeutics, Inc. (RNAC), sold 160,736 shares at $16.33 ($2.8M) on 2024-11-14, disclosed to the SEC on 2024-11-18.
Open-market sale of $2.8M RNAC by Chief Technology Officer. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Something here stands out, but not much.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $16.33 | 21,900 | $358K | 12.7% |
| 2 | $16.33 | 21,900 | $358K | 12.7% |
| 3 | $17.06 | 4,000 | $68K | 2.4% |
| 4 | $17.20 | 22,068 | $380K | 13.5% |
| 5 | $17.20 | 22,068 | $380K | 13.5% |
| 6 | $18.19 | 16,672 |
| $303K |
| 10.8% |
| 7 | $18.19 | 16,672 | $303K | 10.8% |
| 8 | $18.58 | 17,728 | $329K | 11.7% |
| 9 | $18.58 | 17,728 | $329K | 11.7% |
| Total | $17.47 avg | 160,736 | $2.8M | 100% |
| Filing → |
| RNAC | SELL | 2024-11-21 | $1.2M | — | Filing → |